ghisulal dewasi

Mr. ghisulal dewasi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2025 in Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
GDghisulal dewasi
ghisulal dewasi
PNParikshit Nagda
Parikshit Nagda
GBGurusha Bahl
Gurusha Bahl
VJVivek Jain
Vivek Jain
SGSanjay Kumar Gupta
Sanjay Kumar Gupta
Myostatin (MSTN), a pivotal regulator of skeletal muscle homeostasis, belongs to the TGF-β family and functions as a potent inhibitor of muscle hypertrophy. While physiological muscle hypertrophy is a normal adaptive response, dysregulated or excessive hypertrophy often resulting from myostatin pathway disruption can contribute to rare pathological conditions. As a key molecular checkpoint in myogenesis, myostatin modulates the Akt/mTOR pathway, satellite cell dynamics, and ubiquitin-proteasome-mediated protein degradation. Loss-of-function mutations in the MSTN gene disrupt this inhibitory axis, resulting in excessive muscle growth, a phenomenon extensively studied in both animal models and rare human cases. Myostatin inhibition has emerged as a therapeutic strategy for muscle-wasting disorders such as Duchenne muscular dystrophy (DMD), sarcopenia, and cachexia. However, the systemic ramifications of long-term myostatin blockade necessitate a deeper understanding of its role in muscle physiology and metabolic regulation. This review synthesizes current advancements in myostatin signaling, its interplay with myogenic regulatory factors, therapeutic inhibitors under clinical investigation, and potential translational challenges. While targeting myostatin holds clinical promise, optimizing its therapeutic index requires a precise balance between muscle anabolism and functional integrity.

17 October 2026 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
PDF file
GDghisulal dewasi
ghisulal dewasi
SJSakshi Jain
Sakshi Jain
Ferroptosis is a distinct form of regulated cell death driven by iron-dependent lipid peroxidation and oxidative membrane damage, and it differs fundamentally from apoptosis, necroptosis, and pyroptosis in its molecular mechanisms and execution pathways. Increasing evidence indicates that ferroptosis plays a pivotal role in cancer biology by regulating tumour initiation, progression, metastasis, therapeutic resistance, and interactions within the tumour microenvironment (TME). Dysregulation of iron metabolism, lipid peroxidation, amino acid metabolism, and antioxidant defence systems, including the System Xc⁻–GSH–GPX4, FSP1–CoQ₁₀, GCH1–BH4, and DHODH pathways, collectively determines cellular susceptibility to ferroptosis. Recent studies have further highlighted the contribution of organelle crosstalk, immune cell regulation, and stromal interactions in shaping ferroptotic responses and tumour evolution. In this review, we comprehensively summarise the molecular mechanisms underlying ferroptosis, its regulatory signalling networks, and the major milestones that have advanced the field. We further discuss the multifaceted role of ferroptosis across diverse malignancies, its influence on epithelial–mesenchymal transition, tumour invasion, metastasis, and immune modulation, and its emerging significance in overcoming resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy. In addition, we critically evaluate recent progress in ferroptosis-based therapeutic strategies, including nanomedicine, combination therapies, and translational advances, while highlighting current clinical challenges such as tumour heterogeneity, limited pharmacodynamic biomarkers, and safety concerns. Collectively, ferroptosis represents a promising therapeutic vulnerability that bridges fundamental cancer biology with precision oncology. Continued development of biomarker-guided patient stratification, targeted drug delivery systems, and rational combination strategies is expected to accelerate the clinical translation of ferroptosis-based therapies and improve outcomes for patients with refractory and treatment-resistant cancers.

19 June 2026 in Dolor
Verified
Journal Article
Closed access
GDghisulal dewasi
ghisulal dewasi
JVJai Singh Vaghela
Jai Singh Vaghela
MSMeetakshi Saraf
Meetakshi Saraf
SJSakshi Jain
Sakshi Jain
Contenido disponible solo en idioma Inglés.

21 October 2026 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
JGJanesh Kumar Gautam
Janesh Kumar Gautam
DPDevprajy Parashar
Devprajy Parashar
GDghisulal dewasi
ghisulal dewasi
TRTulasie R
Tulasie R
JGJaryir Gibi
Jaryir Gibi
PBPANKAJ BHARDWAJ
PANKAJ BHARDWAJ
Oral cancer remains a major public health concern in India, accounting for a significant proportion of cancer-related morbidity and mortality. Early detect

13 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
GDghisulal dewasi
ghisulal dewasi
PNParikshit Nagda
Parikshit Nagda
SJSakshi Jain
Sakshi Jain
SSShivam Soni
Shivam Soni
Effective postoperative pain control is essential following laparoscopic cholecystectomy, yet the analgesic value of a standardised 150 mg preoperative dose of pregabalin has not been clearly established. This systematic review and meta-analysis synthesised evidence from seven randomised controlled trials published between 2008 and 2025 to evaluate the efficacy and safety of pregabalin when administered before surgery. Four trials reported 24-hour postoperative pain scores, and pooled analysis demonstrated that pregabalin significantly reduced pain compared with control (SMD = –0.80; 95% CI: –1.42 to –0.18; p = .01), although heterogeneity was high (I² = 81%). Pregabalin also produced notable reductions in opioid consumption, including fentanyl (SMD = –1.24; p = .002) and tramadol (SMD = –4.21; p = .002), again with considerable variability across studies. Sedation was slightly increased but did not reach statistical significance, and there were no significant differences in postoperative nausea, vomiting, or headache. Sensitivity analyses supported the stability of these findings. Overall, the results indicate that a single 150 mg preoperative dose of pregabalin meaningfully reduces postoperative pain and opioid requirements following laparoscopic cholecystectomy while maintaining an acceptable safety profile, supporting its use as part of a multimodal analgesic strategy.